https://www.nasdaq.com/press-release/bridgebio-pharma-reports-month-12-topline-results-from-phase-3-attribute-cm-study
https://www.nasdaq.com/press-release/bridgebio-pharma-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-2021-12
https://www.nasdaq.com/press-release/bridgebio-pharma-and-helsinn-group-announce-strategic-collaboration-to-co-develop-and
https://www.nasdaq.com/press-release/bridgebio-pharma-and-helsinn-group-announce-strategic-collaboration-to-co-develop-0
https://www.nasdaq.com/press-release/bridgebio-pharma-inc.-secures-up-to-%24750-million-in-non-dilutive-debt-financing-2021
https://www.nasdaq.com/press-release/bridgebio-pharma-reports-third-quarter-2021-financial-results-and-business-update
https://www.nasdaq.com/press-release/bridgebio-pharma-announces-dosing-of-first-patient-in-phase-1-2-trial-of
https://www.nasdaq.com/press-release/bridgebio-pharma-announces-collaborations-with-columbia-university-and-mount-sinai-to
https://www.nasdaq.com/press-release/bridgebio-pharma-inc.-appoints-pioneering-national-leader-in-genomics-and-workforce
https://www.nasdaq.com/press-release/bridgebio-pharma-announces-progress-in-its-kras-portfolio-new-gene-therapy-programs
https://www.nasdaq.com/press-release/bridgebio-pharma-announces-first-publication-of-preclinical-data-for-its-potentially
https://www.nasdaq.com/press-release/bridgebio-pharma-to-host-virtual-rd-day-on-october-12-2021-2021-10-06
https://www.nasdaq.com/press-release/bridgebio-pharma-announces-updated-phase-2b-data-for-encaleret-in-autosomal-dominant
https://www.nasdaq.com/press-release/bridgebio-pharma-receives-fda-fast-track-designation-for-investigational-therapy-for
https://www.nasdaq.com/press-release/bridgebio-pharma-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-2021-09
https://www.nasdaq.com/press-release/bridgebio-pharma-and-lianbio-announce-first-patient-treated-in-phase-2a-trial-of
https://www.nasdaq.com/press-release/bridgebio-pharma-inc.-appoints-finance-and-pharmaceutical-leaders-fred-hassan-andrea
https://www.nasdaq.com/press-release/bridgebio-pharma-inc.-reports-second-quarter-2021-financial-results-and-business
https://www.nasdaq.com/press-release/bridgebio-pharma-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-2021-08
https://www.nasdaq.com/press-release/bridgebio-announces-clinical-collaboration-with-bristol-myers-squibb-to-study-bbp-398
https://www.nasdaq.com/press-release/bridgebio-pharma-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-2021-07
https://www.nasdaq.com/press-release/bridgebio-pharma-announces-collaborations-with-three-academic-research-institutions
https://www.nasdaq.com/press-release/bridgebio-pharma-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-2021-06
https://www.nasdaq.com/press-release/bridgebio-pharma-receives-fda-fast-track-designation-for-encaleret-for-the-treatment
https://www.nasdaq.com/press-release/bridgebio-pharmas-affiliate-qed-therapeutics-and-partner-helsinn-group-announce-fda-1
https://www.nasdaq.com/press-release/bridgebio-pharmas-affiliate-qed-therapeutics-and-partner-helsinn-group-announce-fda
https://www.nasdaq.com/press-release/bridgebio-pharmas-affiliate-qed-therapeutics-and-partner-helsinn-group-announce-fda-0
https://www.nasdaq.com/press-release/bridgebio-pharma-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-2021-05
https://www.nasdaq.com/press-release/bridgebio-pharma-receives-fda-fast-track-designation-for-investigational-gene-therapy
https://www.nasdaq.com/press-release/bridgebio-pharma-inc.-reports-first-quarter-2021-financial-results-and-business
https://www.nasdaq.com/press-release/bridgebio-pharma-and-the-university-of-california-san-diego-announce-collaboration-to
https://www.nasdaq.com/press-release/bridgebio-pharma-inc.-and-uc-davis-establish-collaboration-to-transform-research-into
https://www.nasdaq.com/press-release/bridgebio-pharma-inc.-and-roswell-park-establish-collaboration-to-translate
https://www.nasdaq.com/press-release/bridgebio-pharma-inc.-and-oregon-health-science-university-establish-collaboration-to
https://www.nasdaq.com/press-release/bridgebio-pharma-inc.-and-the-lundquist-institute-collaborate-to-advance-treatments
https://www.nasdaq.com/press-release/bridgebio-pharma-inc.-and-glyconet-initiate-collaboration-to-discover-potential
https://www.nasdaq.com/press-release/bridgebio-pharma-and-brown-university-announce-partnership-to-drive-the-advancement
https://www.nasdaq.com/press-release/bridgebio-pharma-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-2021-04
https://www.nasdaq.com/press-release/bridgebio-pharmas-affiliate-qed-therapeutics-and-helsinn-group-announce-strategic
https://www.nasdaq.com/press-release/bridgebio-pharma-announces-proof-of-concept-data-of-encaleret-in-adh1-at-the
https://www.nasdaq.com/press-release/bridgebio-pharma-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-2021-03
https://www.nasdaq.com/press-release/bridgebio-pharma-and-affiliate-origin-biosciences-announce-fda-approval-of-nulibrytm
https://www.nasdaq.com/press-release/bridgebio-pharma-inc.-reports-fourth-quarter-and-full-year-2020-financial-results-and
https://www.nasdaq.com/press-release/bridgebio-pharma-to-announce-proof-of-concept-data-from-adh1-at-the-endocrine
https://www.nasdaq.com/press-release/bridgebio-pharma-and-affiliate-ml-bio-solutions-announce-dosing-of-first-patient-in
https://www.nasdaq.com/press-release/bridgebio-pharma-inc.-announces-pricing-of-secondary-offering-of-common-stock-2021-02
https://www.nasdaq.com/press-release/bridgebio-pharma-inc.-announces-launch-of-secondary-offering-of-common-stock-2021-02
https://www.nasdaq.com/press-release/bridgebio-pharma-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-2021-02
https://www.nasdaq.com/press-release/bridgebio-pharma-and-affiliate-venthera-announce-dosing-of-first-patient-in-phase-1-2
https://www.nasdaq.com/press-release/bridgebio-pharma-inc.-announces-completion-of-merger-with-eidos-therapeutics-inc.
https://www.nasdaq.com/press-release/bridgebio-pharma-inc.-prices-upsized-offering-of-%24650-million-convertible-senior
https://www.nasdaq.com/press-release/bridgebio-pharma-inc.-announces-proposed-offering-of-%24400-million-convertible-senior
https://www.nasdaq.com/press-release/stockholders-of-bridgebio-pharma-inc.-and-eidos-therapeutics-inc.-approve-bridgebio
https://www.nasdaq.com/press-release/bridgebio-pharma-inc.-and-eidos-therapeutics-inc.-announce-january-21-2021-election
https://www.nasdaq.com/press-release/bridgebio-pharma-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-2021-01
https://www.nasdaq.com/press-release/leading-independent-proxy-advisory-firm-iss-recommends-bridgebio-pharma-and-eidos
https://www.nasdaq.com/press-release/ucsf-and-bridgebio-pharma-collaborate-to-accelerate-the-development-of-therapies-for
https://www.nasdaq.com/press-release/bridgebio-pharma-and-maze-therapeutics-establish-joint-venture-to-advance-precision
https://www.nasdaq.com/press-release/bridgebio-pharma-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-2020-12
https://www.nasdaq.com/press-release/bridgebio-pharma-and-affiliate-qed-therapeutics-announce-fda-acceptance-of-new-drug
https://www.nasdaq.com/press-release/bridgebio-pharma-and-affiliate-navire-pharma-announce-dosing-of-first-patient-in
https://www.nasdaq.com/press-release/bridgebio-pharma-inc.-reports-third-quarter-2020-financial-results-and-business
https://www.nasdaq.com/press-release/bridgebio-pharma-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-2020-11
https://www.nasdaq.com/press-release/bridgebio-pharma-and-affiliate-phoenix-tissue-repair-announce-first-patient-dosing-in
https://www.nasdaq.com/press-release/bridgebio-pharma-inc.-and-the-university-of-colorado-anschutz-medical-campus
https://www.nasdaq.com/press-release/salk-institute-and-bridgebio-pharma-collaborate-to-advance-therapies-for-genetically
https://www.nasdaq.com/press-release/bridgebio-pharma-and-eidos-therapeutics-announce-merger-agreement-2020-10-05
https://www.nasdaq.com/press-release/bridgebio-pharma-and-affiliate-origin-biosciences-announces-fda-acceptance-of-its-new
https://www.nasdaq.com/press-release/bridgebio-pharma-to-host-virtual-rd-day-on-september-29-2020-2020-09-22
https://www.nasdaq.com/press-release/bridgebio-pharmas-calcilytix-therapeutics-initiates-phase-2-study-of-encaleret-for
https://www.nasdaq.com/press-release/bridgebio-pharma-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-2020-09
https://www.nasdaq.com/press-release/bridgebio-pharma-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-2020-08
https://www.nasdaq.com/press-release/bridgebio-pharma-inc.-reports-second-quarter-2020-financial-results-and-business
https://www.nasdaq.com/press-release/bridgebio-pharma-expands-reach-into-china-and-other-major-asian-markets-through
https://www.nasdaq.com/press-release/ivy-brain-tumor-center-and-bridgebio-pharmas-qed-therapeutics-announce-dosing-of
https://www.nasdaq.com/press-release/bridgebio-pharmas-qed-therapeutics-doses-first-child-in-phase-2-clinical-trial-of-the
https://www.nasdaq.com/press-release/bridgebio-pharmas-phoenix-tissue-repair-to-highlight-interim-phase-1-2-study-data-in
https://www.nasdaq.com/press-release/bridgebio-pharma-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-2020-07
https://www.nasdaq.com/press-release/bridgebio-pharma-inc.-appoints-biotech-trailblazers-brent-saunders-and-randy-scott
https://www.nasdaq.com/press-release/bridgebio-pharma-and-university-of-florida-establish-collaboration-to-advance
https://www.nasdaq.com/press-release/bridgebio-pharma-inc.-enters-into-collaboration-agreement-with-johns-hopkins
https://www.nasdaq.com/press-release/bridgebio-pharmas-ml-bio-solutions-announces-dosing-of-first-subject-in-phase-1
https://www.nasdaq.com/press-release/bridgebio-pharma-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-2020-06
https://www.nasdaq.com/press-release/bridgebio-pharmas-qed-therapeutics-presents-data-on-infigratinib-in
https://www.nasdaq.com/press-release/bridgebio-pharmas-phoenix-tissue-repair-provides-updates-to-its-recessive-dystrophic
https://www.nasdaq.com/press-release/bridgebio-pharma-inc.-reports-first-quarter-2020-financial-results-and-business
https://www.nasdaq.com/press-release/bridgebio-pharmas-qed-therapeutics-announces-preclinical-data-demonstrating-potential
https://www.nasdaq.com/press-release/bridgebio-pharma-inc.-to-present-at-upcoming-investor-conference-2020-05-06
https://www.nasdaq.com/press-release/bridgebio-pharma-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-2020-05
https://www.nasdaq.com/press-release/bridgebio-pharma-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-2020-04
https://www.nasdaq.com/press-release/bridgebio-pharmas-qed-therapeutics-announces-dosing-of-first-patients-in-phase-3-and
https://www.nasdaq.com/press-release/bridgebio-pharma-inc.-prices-upsized-offering-of-%24475-million-convertible-senior
https://www.nasdaq.com/press-release/bridgebio-pharma-inc.-announces-proposed-offering-of-%24350-million-convertible-senior
https://www.nasdaq.com/press-release/bridgebio-pharma-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-2020-03
https://www.nasdaq.com/press-release/bridgebio-pharma-reports-fourth-quarter-and-full-year-2019-financial-results-and
https://www.nasdaq.com/press-release/bridgebio-pharma-inc.-appoints-ronald-j.-daniels-to-its-board-of-directors-2020-02-24
https://www.nasdaq.com/press-release/bridgebio-pharma-and-eidos-therapeutics-to-present-at-upcoming-investor-conferences
https://www.nasdaq.com/press-release/bridgebio-pharma-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-2020-02
https://www.nasdaq.com/press-release/bridgebio-pharma-grows-pipeline-to-20-genetic-medicines-with-four-assets-focused-on
https://www.nasdaq.com/press-release/bridgebio-pharmas-gene-therapy-subsidiaries-enter-strategic-partnership-with-catalent
https://www.nasdaq.com/press-release/bridgebio-pharmas-qed-therapeutics-receives-fast-track-designation-for-infigratinib
https://www.nasdaq.com/press-release/bridgebio-pharma-inc.-to-present-at-upcoming-investor-conference-2019-12-19
https://www.nasdaq.com/press-release/bridgebio-pharmas-origin-biosciences-enters-partnership-with-medison-to-commercialize
https://www.nasdaq.com/press-release/bridgebio-pharma-inc.-appoints-industry-leader-jennifer-cook-as-new-board-member-2019
https://www.nasdaq.com/press-release/bridgebio-pharma-inc.-appoints-eli-wallace-as-chief-scientific-officer-in-residence
https://www.nasdaq.com/press-release/bridgebio-pharma-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-2019-12
https://www.nasdaq.com/press-release/bridgebio-pharmas-origin-biosciences-initiates-rolling-submission-of-new-drug
https://www.nasdaq.com/press-release/bridgebio-pharma-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-2019-11
https://www.nasdaq.com/press-release/bridgebio-pharma-reports-third-quarter-2019-financial-results-and-highlights
https://www.nasdaq.com/press-release/bridgebio-pharma-gene-therapy-subsidiaries-present-data-demonstrating-potential-in
https://www.nasdaq.com/press-release/qed-and-parent-company-bridgebio-announce-preclinical-data-supporting-tolerability
https://www.nasdaq.com/press-release/bridgebio-pharma-terminates-merger-process-with-its-subsidiary-eidos-therapeutics
